Evidence map›Paper›PMID 8604293›Full record

ArticleNucleic acids research1996

Activation domains of transcription factors mediate replication dependent transcription from a minimal HIV-1 promoter.

R D Williams, B A Lee, S P Jackson, N J Proudfoot

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. The sly-miR166-SlyHB module acts as a susceptibility factor during ToLCNDV infection.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Regulation of HIV-1 transcription.Gene expression · 1999
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

R D WilliamsSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
B A Lee
S P Jackson
N J Proudfoot
University of Oxford · GBWellcome/Cancer Research UK Gurdon Institute · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Transcription from a minimal HIV-1 promoter containing the three Sp1 binding sites and TATA box can be activated without Tat by template DNA replication. Here we show that this activation can also be mediated by recombinant GAL4 fusion proteins containing the activation domains of Sp1, VP16 or CTF (or by full-length GAL4) targeted to the HIV-1 promoter by replacing the Sp1 sites with five GAL4 binding sites. Thus Sp1 is not unique in its ability to mediate replication activated transcription, although the degree of processivity elicited by the different activators varied significantly from strongly processive (GAL4-VP16) to relatively non-processive (GAL4-Sp1 or -CTF). Processive GAL4-VP16-activated transcription, but not efficient initiation, required multiple GAL4 binding sites. In the presence of Tat, transcription with GAL4-SP1 and GAL4-CTF was further activated (principally at the level of processivity) but GAL4-VP16-potentiated transcription was only slightly stimulated. The Tat-dependent switch from non-processive to fully processive transcription was particularly marked for GAL4-Sp1, an effect which may be relevant to the selection of Sp1 binding sites by the HIV-1 promoter.

Indexed as

Transcriptional ActivationBase SequenceDNA ReplicationDNA, ViralGene Transfer TechniquesHeLa CellsHIV-1HumansMolecular Sequence DataPromoter Regions, GeneticTranscription FactorsDNA, ViralTranscription Factors

Identifiers

PMID8604293
PMCPMC145701
OpenAlexW1975303161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.